Comparative Pharmacology
Head-to-head clinical analysis: ILUVIEN versus ORAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILUVIEN versus ORAPRED.
ILUVIEN vs ORAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. It also inhibits cytokine production and endothelial cell adhesion molecule expression.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune responses, and adrenal function.
Intravitreal implant containing 0.19 mg fluocinolone acetonide, designed to release drug over approximately 36 months. Administered as a single injection into the vitreous cavity of the eye.
5-60 mg orally once daily or divided as 5-15 mg every 4-12 hours; adjust based on response and condition.
None Documented
None Documented
Intravitreal terminal half-life of fluocinolone acetonide from the Iluvien implant is approximately 30 months (range 18-36 months), providing sustained release over 36 months in the vitreous cavity.
4-5 hours (terminal); prolonged in renal impairment (up to 12+ hours in anuria) and hepatic dysfunction; clinical context: dosing interval adjustment in severe renal failure
Fluocinolone acetonide is primarily eliminated via hepatic metabolism and subsequent fecal/biliary excretion. Approximately 50-70% of a dose is excreted in feces as metabolites, with less than 20% recovered in urine as unchanged drug or metabolites.
Renal: approximately 60-80% as unchanged drug and conjugated metabolites; biliary/fecal: minor (5-10%)
Category C
Category C
Corticosteroid
Corticosteroid